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Aims To assess the results of transcatheter ablation of cardiac arrhythmias in Latin America and establish the first Latin
American transcatheter ablation registry.
Methods
and results
All ablation procedures performed between 1 January and 31December 2012were analysed retrospectively. Datawere
obtained on the characteristics and resources of participating centres (public or private institution, number of beds,
cardiac surgery availability, type of room for the procedures, days per week assigned to electrophysiology procedures,
type of fluoroscopy equipment, availability and type of electroanatomical mapping system, intracardiac echo, cryoabla-
tion, and number of electrophysiologists) and the results of 17 different ablation substrates: atrio-ventricular node
reentrant tachycardia, typical atrial flutter, atypical atrial flutter, left free wall accessory pathway, right free wall
accessory pathway, septal accessory pathway, right-sided focal atrial tachycardia, left-sided focal atrial tachycardia, par-
oxysmal atrial fibrillation, non-paroxysmal atrial fibrillation, atrio-ventricular node, premature ventricular complex, idio-
pathic ventricular tachycardia, post-myocardial infarction ventricular tachycardia, ventricular tachycardia in chronic
chagasic cardiomyopathy, ventricular tachycardia in congenital heart disease, and ventricular tachycardias in other struc-
tural heart diseases. Data of 15 099 procedureswere received from120 centres in 13 participating countries (Argentina,
Bolivia, Brazil, Chile, Colombia, Cuba, El Salvador, Guatemala, Mexico, Peru, Dominican Republic, Uruguay, and Vene-
zuela). Accessory pathway was the group of arrhythmias most frequently ablated (31%), followed by atrio-ventricular
node reentrant tachycardia (29%), typical atrial flutter (14%), and atrial fibrillation (11%). Overall success was 92%
with the rate of global complications at 4% and mortality 0.05%.
Conclusion Catheter ablation in Latin America can be considered effective and safe.
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Introduction
Transcatheter ablation of cardiac arrhythmias was successfully intro-
duced into daily clinical practice over 30 years ago.1,2 Since then,
surveys and multicentre registries have mainly been reported from
centres across the Europe and the USA,3–5 whereas in Latin
America registries are limited to a few countries.6,7 Therefore, the
LatinAmerican Society of Electrophysiology andCardiac Stimulation
(SOLAECE) decided to compile the first Catheter Ablation Registry
in Latin America.
* Corresponding author. Tel: +54 291 4552514; fax: +54 291 4552514. E-mail address: robertokeegan@gmail.com
† Name of investigators and centres are reported in online Appendix.
Published on behalf of the European Society of Cardiology. All rights reserved.& The Author 2015. For permissions please email: journals.permissions@oup.com.
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Methods
The registry was designed to retrospectively analyse all ablations,
either first-time or re-do procedures, performed between 1
January and 31 December 2012. Voluntary invitations to all local
representativeswere issuedby SOLAECE through the scientific elec-
trophysiology (EP) societies to complete an online form related to
the centre resources and all transcatheter ablation procedures
conducted. Data collected covered the centres’ resources, different
ablation substrates, and the success and complication rates of proce-
dures. Every participating investigator had to be affiliated to any
scientific EP society and to sign up an agreementof reliability and con-
fidentiality before data entering.
Centre-related information: Public or private institution, number of
beds, cardiac surgery availability, type of room for the procedures
[EP laboratory, catheterization (Cath) laboratory, or operating
room], days perweek assigned toEPprocedures, typeof fluoroscopy
equipment, availability and typeof electroanatomicalmapping system
(Cartow, EnSitew, or both), intracardiac echo, cryoablation, and
number of electrophysiologists.
Seventeen ablation substrates were analysd: Atrio-ventricular node
reentrant tachycardia (AVNRT), typical atrial flutter (AF), atypical
AF, left freewall accessory pathway (left AP), right freewall accessory
pathway (right AP), septal accessory pathway (septal AP), right-sided
focal atrial tachycardia (right AT), left-sided focal atrial tachy-
cardia (left AT), paroxysmal atrial fibrillation (PAF), non-PAF, atrio-
ventricular node (AVN), premature ventricular complex (PVC),
idiopathic ventricular tachycardia (VT), post-myocardial infarction
ventricular tachycardia (MIVT), ventricular tachycardia in chronic
chagasic cardiomyopathy (Chagas VT), ventricular tachycardia in
congenital heart disease (congenitalVT), andventricular tachycardias
in other structural heart diseases (cardiopathy VT).
Outcomes of the procedures: These included total number of
patients and procedures, success of the procedures, type of catheter
used (4 mm, 8 mm, or irrigated tip), procedureswith radiofrequency
as the power source, cryoablation, fluoroscopy, and electroanatomi-
cal mapping, type of anaesthesia (local, conscious sedation, and
general), and patients with at least one complication during hos-
pitalization. Additionally, the results included specific details of the
complications that arose as a result of treatment: hematoma, arterio-
venous fistula, thrombosis and thrombophlebitis, pneumothorax,
pleural effusion, atrio-ventricular block with and without pacemaker
implantation, pericarditis, pericardial effusion, cardiac tamponade,
myocardial infarction/ischaemia, congestive heart failure /acute pul-
monary edema, transient ischaemic attack, stroke, peripheral embol-
ism, death, or other complications.
Success was determined at the end of the procedure. The defini-
tions of success had been consented for substrates such as
AVNRT, typical and atypical AF, right AP, left AP, septal AP, right
AT, left AT, AVN, and idiopathic VT. Success criteria for more
complex substrates were defined as follows: isolation of all pulmon-
ary veins for PAF; isolation of pulmonary veins plus achievement of
additional end points (i.e. additional lines, complex fractionated
atrial electrogram mapping) for non-PAF and absence of culprit
ventricular complexes 30 min after ablation for PVCs. Post-MIVT,
Chagas VT, congenital VT, and cardiopathy VT ablation procedures
were considered successful if all the monomorphic VTs induced at
the baseline became non-inducible post-ablation.
Results were expressed as average, ranges, and percentages.
Results
Data were received from 120 centres located in Argentina, Bolivia,
Brazil, Chile, Colombia, Cuba, El Salvador, Guatemala, Mexico,
Peru, Dominican Republic, Uruguay, and Venezuela. The total popu-
lationof these 13 countries represents 90%of the population of Latin
America. The average population per centre across the 13 partici-
pating countries was 8 053 176 habitants (656 349 in Argentina
and 16 841 000 in Colombia). The distribution of the participating
centres by country was as follows: 52% from Argentina, 18% from
Brazil, 12% from Mexico, and 18% from the remaining countries.
However, 79% of the procedures were referred by two countries:
Brazil (45%) and Argentina (34%). Forty-three centres (36%)
performed over 100 procedures in the 1 year period, 24 centres
(20%) performed between 50 and 100, and 53 centres (44%) per-
formed fewer than 50 procedures. Table 1 shows the number of
What’s new?
† This is the first information of catheter ablation in Latin
America as a result of a multicentre registry including a large
number of procedures.
† Efficacy and safety are considered similar to other places
worldwide.
† According to the results, ventricular tachycardia ablation in cha-
gasic patients could be considered a challenging procedure.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Number of centres participating in the Latin
American Registry that performed ablations in the 17
substrates analysed
Substrate Centres
Atrio-ventricular nodal reentrant tachycardia 116 (97%)
Typical Atrial flutter 105 (88%)
Atypical Atrial flutter 56 (47%)
Left Accessory Pathways 113 (94%)
Right Accessory Pathways 83 (69%)
Septal Accessory Pathways 102 (85%)
Right Focal atrial tachycardia 77 (64%)
Left Focal atrial tachycardia 43 (36%)
Paroxysmal atrial fibrillation 56 (47%)
Not paroxysmal atrial fibrillation 38 (32%)
Atrioventricular node ablation 75 (63%)
Premature ventricular complexes 70 (58%)
Idiopathic VT 80 (67%)
Post-myocardial infarction ventricular tachycardia 42 (35%)
Ventricular tachycardia in Chagas disease 22 (18%)
Congenital VT 7 (6%)
Cardiopathy VT 21 (18%)
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the centres that performed ablations in the 17 categories of ablation
substrate (Figure 1).
Centre-related information
Of the participating centres, 63% were private, whereas 25% were
public and 12% academic (university hospitals), with average beds
per centre of 235 (10–1000). Cardiac surgery was available in 109
centres (91%). An EP laboratory was available in 72 centres (60%),
with the remaining 48 (40%) centres performing the procedures in
Cath laboratories or operating rooms. On average, 2.81–4 EP proce-
dures were conducted each week.
Fluoroscopywas provided by an angiographer in 67 centres (56%)
while aC-archwith rotating anodewasused in 40 (33%) centres and a
C-arch with a fixed anode in only 4 (3%) centres. Information about
the type of fluoroscopy equipment was not provided by nine of the
centres (8%).
Fifty-nine centre (49%) had electroanatomical mapping avai-
lable including 16 with Cartow mapping, 34 with EnSitew, and 9
with both, whereas 24 centres (20%) had intracardiac echocardiog-
raphy (5 from Argentina, 5 from Mexico, 4 from Brazil, 3 from
Uruguay, 3 from Venezuela, 2 from Colombia, 1 from Peru, and 1
fromEl Salvador).Only four centres (3%)were equippedwith cryoa-
blation facilities (three from Argentina and one from Mexico).
Sixty centres (50%) had a fellowship programme as part of their
working structure and organization.
Ablation substrates and resources
Atrio-ventricular node reentrant tachycardiawas themost frequent-
ly treated substrate. However, after substrate grouping, accessory
pathwayswere themost frequently performedprocedure (31%), fol-
lowed by AVNRT (29%), typical AF (14%), and atrial fibrillation
(11%). These four ablation substrate groups represented 85% of
the procedures overall, whereas ventricular arrhythmias repre-
sented less than 10% of the referred ablations (Figures 2 and 3).
Atrial fibrillation ablation was performed in 63 centres (52%)
and the average annual number of procedures per centre was 26.
Only five centres performed 100 or more procedures. Most of
the centres ablated PAF and non-PAF while 15 centres only treated
paroxysmal AF.
The 4 mm tip was the most commonly used ablation catheter
(66%). The irrigated tip was used in 20% of the procedures, with
the8 mmablationcathetercounting for the remaining14%.Radiofre-
quency was the predominant power source used, since cryoablation
was chosen in only 25 procedures (0.17%). Electroanatomical
mapping was used in 20% of the cases.
Local anaesthesia and conscious sedation were used most fre-
quently,with only 18%of thepatients undergoing general anaesthesia.
Ablation results
The total number of procedures included in the analysis was 15 099
and the total number of patients 14.349. Thus, 750 of procedures
(5%)were performed by arrhythmia recurrence and/or unsuccessful
previous ablation. Overall success was achieved in 92% of the proce-
dures (13 838). The success rate per substrate is shown in Figures 4
and 5. The complication rate among all procedures was 4%.
Figures 6 and 7 show complication rates per substrate and the preva-
lence of different complications. Table 2 summarizes the number of
procedures and outcomes of different substrates in each country.
AVNRT
29%
AF
14%
AT
4%
AP
31%
IDIOPATHIC
VENTRICULAR
6% NON-IDIOPATHIC VTs
3%
Afib
11% AVN2%
Figure 2 Grouped substrates. AP, accessory pathways; AVNRT,
atrio-ventricular nodal reentrant tachycardia; AF, atrial flutter; Afib,
atrial fibrillation; AT, focal atrial tachycardia; AVN, atrio-ventricular
node.
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Figure 1 Total number of procedures conducted for each substrate in the participating centres in the Latin American Registry.
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Eight procedure-related deaths were reported (0.05%): three
of them occurred during a Chagas VT ablation (1.81%), two during
an AVN ablation (0.58%), one during a PAF procedure (0.09%),
one during a right free wall AP (0.08%), and the other one during
AVNRT ablation (0.02%). Substrate grouping revealed a mortality
rate of 0.58% for VT when structural heart disease was present and
of 0.58% for AVN ablation, 0.06% for atrial fibrillation ablation, and
0.02% for AP and AVNRT ablations. The complications related to
mortalitywerepulmonaryembolism(rightAPendocardial/epicardial
ablation in a patient with Ebstein anomaly, and AVN ablation),
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Figure 5 Per substrate complications in the 17 ablation substrates analysed.
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Figure 4 Success rates in ventricular arrhythmias.
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Figure 3 Success rates in supraventricular arrhythmias.
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tamponade (AVNRT and Chagas VT), tamponade associated to
severe aortic valvular insufficiency (Chagas VT), and unknown in
three cases (PAF ablation, AVN ablation, and Chagas VT ablation).
Discussion
Even though almost 80%of the procedures came from two countries
(Brazil and Argentina), the first Latin American multicentre retro-
spective catheter ablation registry can be considered representative
of transcatheter ablation procedures in Latin American as the
population of the 13 countries participating accounted for themajor-
ity of the population living in this region of the world.
When the centre-related information was analysed, we observed
some limitations regarding infrastructure and technology resources.
Less than 50% of the centres had a dedicated EP laboratory or
an electroanatomical mapping system. This could be related to the
economic situation in Latin America, as the majority of countries
are developing countries.
Even though thedistributionof the ablated arrhythmias is similar to
other registries with the majority of ablations performed for AVRT,
accessory pathways, and atrial flutter, based on the number of the
centres that performed more complex ablations, such as atrial fibril-
lation and VT with structural heart diseases, it is possible that these
procedures are underused for treating these types of arrhythmias.
The global success ratewas lower and the complication rate higher
than other registries.5 However, in the analysis of procedure success
rates, atrial fibrillation and post-MIVT data were included in the Latin
American Registry, but not in the comparison registries. In the Latin
American Registry, haematoma accounted for more than 50% of the
complications reported in all 17 substrates, irrespective of whether
treatment was required. In the other registries, only haematomas
that required treatment such as blood transfusion and/or surgical
intervention were included. The success rate in simpler ablations
was similar. On the other hand, the rate of complications in atrial
fibrillation ablation was higher than expected8 but similar to the
European AFib ablation registry published recently.9,10 This finding
could be associated with the low numbers of procedures performed
yearly for this arrhythmia.
Finally, it is important to mention that this is the first registry that
analysed VT ablation in Chagas disease. Even though Chagas
disease is endemic in many countries in Latin America, globalization
and migration have increased the likelihood of treatment of patients
with VT as a direct result of Chagas disease elsewhere in the world.
Consequently, the data on VT ablation in Chagas disease could
provide important information regarding the performance of this
challenging ablation. As reported here, this arrhythmia had the
lowest success rate and the highest rate of complications. This
could be related to the complexity of the arrhythmia itself, the com-
plexity of the procedure (an epicardial access is frequently required),
and the frequently poorclinical conditionof thepatients at the timeof
the procedure, as in many cases incessant VT and electrical storm is
the indication for ablation.
Limitations
Owing to lack of information of total number of centres performing
catheter ablation in Latin America, the participation degree of the
centres as a representative sample is missing.
No auditing procedure was established to assess the reliability of
collected data and outcomes of ablations.
According to the registrydesign noprospectivedata such as recur-
rence of arrhythmias after the procedure or complication rate
beyond discharge the patient were available.
Conclusions
Catheter ablation in Latin America can be considered effective and
safe. However, it may be underutilized, especially for more complex
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Figure 6 Prevalence of the different complications recorded
from all of the 17 ablation substrates analysed.
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Figure 7 (Representative figure): First Latin American Catheter
Ablation Registry: countries, centres, and procedures.
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Table 2 Number of procedures and outcomes of different substrates in each country
Country Centres Procedures Average
per centre
per year
AP AVNRT AFL AF AT AVN IVA Chagas VT Post-MIVT VT other Success (%) Complications (%)
Brazil 18 6853 381 2203 2180 731 742 173 97 410 125 146 46 89 4
Argentina 63 5071 80 1375 1443 946 613 237 96 258 32 55 16 92 4
Venezuela 4 807 202 167 232 87 124 38 25 93 5 22 14 92 6
Mexico 12 806 67 262 202 116 68 34 67 45 0 9 3 95 3
Colombia 3 425 142 66 95 88 72 9 24 38 4 0 29 97 4
Cuba 2 356 178 204 97 29 0 9 9 8 0 0 0 90 1
Uruguay 4 300 75 81 85 59 13 17 14 22 0 3 6 91 3
Peru 4 259 65 159 30 40 0 4 7 19 0 0 0 90 5
Chile 1 71 71 10 10 18 17 6 2 4 0 4 0 96 0
Dominican Republic 5 65 13 28 21 5 0 3 1 7 0 0 0 95 0
Guatemala 1 37 37 31 2 1 0 2 1 0 0 0 0 86 3
El Salvador 1 32 32 13 9 3 0 1 1 4 0 1 0 84 13
Bolivia 2 17 9 4 10 3 0 0 0 0 0 0 0 100 0
AP, accessory pathways; AVNRT, atrio-ventricular nodal reentrant tachycardia; AFL, atrial flutter; AF, atrial fibrillation; AT, focal atrial tachycardia; AVN, atrioventricular node ablation; IVA, idiopathic ventricular arrhythmias; Chagas VT, ventricular
tachycardia in chronic chagasic cardiomyopathy; post-MIVT, post-myocardial infarction ventricular tachycardia; VT other, ventricular tachycardia in congenital and other structural heart disease.
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arrhythmias. Perhaps with improvements to infrastructure andmore
technical resources greater numbers of patientswould gain access to
ablation facilities in Latin America and improve the overall results.
Supplementary material
Supplementary material is available at Europace online.
Conflict of interest: none declared.
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A leadless solution
Fleur V.Y. Tjong*, Kirsten M. Kooiman, Joris R. de Groot, and Reinoud E. Knops
Heart Center, Department of Cardiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands
* Corresponding author. Tel: +31 20 566 6555; fax: +31 20 696 2609. E-mail Address: f.v.tjong@amc.uva.nl
A 78-year-old male with a history of complicated
diabetes, peripheral arterial and coronary dis-
ease, hypertension, and atrial fibrillation with a
VVI pacemaker was referred to our tertiary
centre with a bilateral pocket infection. Manage-
ment of this infection was suboptimal and not
according to the current guidelines. The initial left-
sided pocket infection was treated elsewhere by
explanting the pulse generator, leaving the lead
cut and capped in situ (Panel A, arrow head).
During this procedure a new pacemaker system
was implanted contra laterally (Panel A, arrow).
Despite long-term antibiotic treatment, the infec-
tion recurred on the second pacemaker system. This formed the indication for total pacemaker system explantation. Re-implantation
of a pacemaker in previously bilaterally infected pectoral tissue was contraindicated and traditional solutions (epicardial or transfemoral
lead placement) have a considerable riskof complications. Apercutaneous leadless pacemaker (St JudeMedical) provided a newandbetter
option. However, only limited clinical data are available to date and perforation of this device has been described. The entire pacemaker
system and capped lead were successfully explanted using laser. Two days later the leadless cardiac pacemaker was implanted in the right
ventricular apex (Panel B, arrow). Tenmonths post implant, the pacing performancewaswithin the accepted range and no signs of local or
systemic infection were present.
The full-length version of this report can be viewed at: http://www.escardio.org/communities/EHRA/publications/ep-case-reports/
Documents/A_leadless_solution.pdf.
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